Being a potent activator of the mitogenic MAPK signaling, HB-EGF has been studied primarily in cancers as an oncogenic target, for its role in activating cell proliferation and anchorage-independent growth through autocrine signaling (Ray et al., 2014; Hsieh et al., 2017). This evidence concerns the gene HBEGF and cancer.